Takeda’s EXKIVITY secures China’s NMPA approval for type of NSCLC
The approval was based on the results from a phase 1/2 clinical trial which showed EXKIVITY’s clinical benefit…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Jan 23
The approval was based on the results from a phase 1/2 clinical trial which showed EXKIVITY’s clinical benefit…
10 Jan 23
The sample cohort primarily contains DNA of African Americans, who are said to be currently underrepresented in research…
09 Jan 23
Amryt Pharma is a commercial-stage biopharmaceutical firm that acquires, develops and commercialises treatments to help improve the lives…
04 Jan 23
The patent protects against compounded, unapproved copies of Mitosol, the company's flagship medication, in future applications
03 Jan 23
Under the deal, both firms will use their combined chemistry platforms to create a biopharma that will develop…
28 Dec 22
The deal includes the purchase of remaining financial obligations for anti-CCR8 antibody in development as part of Gilead's…
27 Dec 22
Under the agreement, Hikma will develop and commercialise toripalimab in all its MENA markets and will have the…
26 Dec 22
The approval was based on positive results from the phase II GO29781 study of Lunsumio which showed high…
23 Dec 22
The approval is backed by data from the CAPELLA phase 2/3 trial which assessed Sunlenca in combination with…
21 Dec 22
As part of the Summit, discussions will focus on the metaverse and the opportunities it has to impact…